News headlines about Miragen Therapeutics (NASDAQ:MGEN) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Miragen Therapeutics earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 44.7229073903218 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news headlines that may have effected Accern’s rankings:
- What is ATR in technical analysis? Miragen Therapeutics, Inc. (MGEN) – Wall Street Morning (wallstreetmorning.com)
- Miragen Therapeutics, Inc. (MGEN) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Miragen Therapeutics, Inc. (MGEN) Regains Attentions on Diverse … – Investing News Update (investingbizz.com)
- Miragen Therapeutics, Inc. (MGEN) stock price increased 22.05% from its 20-SMA – The Stocks News (press release) (thestocksnews.com)
- Miragen: Our Take On This RNA Play – Miragen Therapeutics, Inc … – Seeking Alpha (seekingalpha.com)
Miragen Therapeutics stock opened at $7.51 on Thursday. The company has a market capitalization of $227.80, a price-to-earnings ratio of -5.01 and a beta of 1.64. Miragen Therapeutics has a fifty-two week low of $5.01 and a fifty-two week high of $15.91. The company has a current ratio of 13.33, a quick ratio of 13.33 and a debt-to-equity ratio of 0.26.
MGEN has been the topic of a number of recent research reports. Cann reiterated a “buy” rating and issued a $13.00 target price on shares of Miragen Therapeutics in a research note on Friday, February 2nd. Chardan Capital reissued a “buy” rating on shares of Miragen Therapeutics in a report on Tuesday, January 16th. Zacks Investment Research raised Miragen Therapeutics from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a report on Thursday, January 18th. B. Riley initiated coverage on Miragen Therapeutics in a report on Friday, January 5th. They set a “buy” rating and a $15.50 price target on the stock. Finally, Wedbush reissued a “buy” rating and set a $19.00 price target on shares of Miragen Therapeutics in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $16.82.
In other news, Director Bruce Booth bought 545,454 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were purchased at an average cost of $5.50 per share, with a total value of $2,999,997.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Adam Scott Levy bought 9,090 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were purchased at an average cost of $5.50 per share, for a total transaction of $49,995.00. Following the completion of the acquisition, the insider now owns 10,540 shares of the company’s stock, valued at $57,970. The disclosure for this purchase can be found here. 44.40% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: This news story was first posted by BBNS and is the property of of BBNS. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://baseballnewssource.com/2018/03/22/miragen-therapeutics-mgen-given-media-sentiment-score-of-0-12/1925720.html.
About Miragen Therapeutics
Signal Genetics, Inc is a commercial stage, molecular genetic diagnostic company. The Company is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test.
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.